Quince Therapeutics (QNCX) Insider Trading & Ownership $1.84 +0.07 (+3.95%) (As of 11/20/2024 ET) Add Compare Share Share Insider Trades Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Quince Therapeutics (NASDAQ:QNCX) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage16.80%Number OfInsiders Buying(Last 12 Months)4Amount OfInsider Buying(Last 12 Months)$218,148.64Number OfInsiders Selling(Last 12 Months)0 Get QNCX Insider Trade Alerts Want to know when executives and insiders are buying or selling Quince Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address QNCX Insider Buying and Selling by Quarter Ad WealthPressThis Bull Market Indicator called NVDA at $116Every now and again we find an investment idea so incredible we can’t help but share. And today is one of those rare days… Except, today we won't be giving you insight on any one particular stock… But rather, insight on a revolutionary new stock picking indicator… In fact, within the last year, this indicator has become famous for a multitude of reasons… But one of the biggest was because of the buy signal it issued on October 18th, 2022. In fact, on that very day, it said to buy NVDA at $116.37… Anyone who did would be sitting on a tremendously large return today… But even if you missed the original buy signal from October, this incredible indicator issued 11 other buy signals while Nvidia made its epic run…All you have to do is follow this link here Quince Therapeutics Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame * Start Date * End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails8/29/2024Dirk ThyeCEOBuy77,500$0.69$53,475.00 8/21/2024Brendan HannahCOOBuy30,845$0.63$19,432.35 8/20/2024Charles S RyanPresidentBuy48,387$0.65$31,451.55 8/19/2024Brendan HannahCOOBuy2,155$0.58$1,249.90 12/14/2023David LamondDirectorBuy22,627$1.04$23,532.08 12/12/2023David LamondDirectorBuy22,327$1.02$22,773.54 Get Insider Trades Delivered To Your InboxEnter your email address below to receive a concise daily summary of insider buying activity, insider selling activity and changes in hedge fund holdings. 12/7/2023David LamondDirectorBuy19,123$1.01$19,314.23 12/5/2023David LamondDirectorBuy19,123$1.01$19,314.23 12/1/2023David LamondDirectorBuy14,378$0.94$13,515.32 11/29/2023David LamondDirectorBuy14,378$0.98$14,090.44 (Data available from 1/1/2013 forward) QNCX Insider Trading Activity - Frequently Asked Questions Who is on Quince Therapeutics's Insider Roster? The list of insiders at Quince Therapeutics includes Brendan Hannah, Charles S Ryan, David Lamond, Dirk Thye, Margaret Mcloughlin, and Ted Monohon. Learn more on insiders at QNCX. What percentage of Quince Therapeutics stock is owned by insiders? 16.80% of Quince Therapeutics stock is owned by insiders. Learn more on QNCX's insider holdings. Which Quince Therapeutics insiders have been buying company stock? The following insiders have purchased QNCX shares in the last 24 months: Brendan Hannah ($108,231.89), Charles S Ryan ($31,451.55), David Lamond ($340,641.56), Dirk Thye ($263,555.00), and Margaret Mcloughlin ($9,840.00). How much insider buying is happening at Quince Therapeutics? Insiders have purchased a total of 692,283 QNCX shares in the last 24 months for a total of $753,720.00 bought. Which Quince Therapeutics insiders have been selling company stock? The following insider sold QNCX shares in the last 24 months: Ted Monohon ($1,833.58). How much insider selling is happening at Quince Therapeutics? Insiders have sold a total of 1,871 Quince Therapeutics shares in the last 24 months for a total of $1,833.58 sold. Quince Therapeutics Key ExecutivesDr. Dirk Thye M.D. (Age 54)CEO, Chief Medical Officer & Director Compensation: $856.5kDr. Charles S. Ryan J.D. (Age 60)Ph.D., President Compensation: $524.47kMr. Brendan Hannah M.B.A. (Age 38)Chief Business Officer, COO, Chief Compliance Officer and Principal Financial & Accounting Officer Compensation: $607.5kDr. Guenter R. Janhofer M.D.Ph.D., Chief Scientific OfficerMs. Stacy RoughanVice President of Corporate Communications & Investor RelationsMs. Mary Ellen SillivosVice President of Human ResourcesDr. Stewart A. Low Ph.D.Head of Discovery More Insider Trading Tools from MarketBeat Related Companies ATRA Insider Transactions GBIO Insider Transactions CHRS Insider Transactions ADVM Insider Transactions JSPR Insider Transactions DSGN Insider Transactions LYEL Insider Transactions SAGE Insider Transactions KOD Insider Transactions CCCC Insider Transactions Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles Insiders Selling Into 3 Rallies: Investors Should Do the OppositeInsiders Bet Big on These Small Cap StocksHere’s Why Etsy Management Is Investing $1 Billion in BuybacksInsider Buying Signals Upside for These 3 StocksBig Buybacks Announced: 3 Stocks Insiders Are Banking On This page (NASDAQ:QNCX) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Quince Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Quince Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free QNCX Stock Alerts